- Lexaria recently announced the findings of the first two studies from its EPIL-A21-1 animal research program
- The program is designed to assess the effectiveness of patented DehydraTECH(TM)-CBD in reducing or eliminating seizure activity compared to Epidiolex, a CBD-based anti-seizure drug
- The first study evidenced that DehydraTECH-CBD is more efficacious at lower doses than Epidiolex
- The second study demonstrated DehydraTECH-CBD’s enhanced effectiveness; specifically, the formulation acted more rapidly than Epidiolex
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) formulation has demonstrated performance enhancements compared to Epidiolex(R), the first and only FDA-approved CBD medication for the treatment of seizures (https://ibn.fm/iCdk5).
Initiated in March this year and conducted by a leading US-based independent laboratory, the EPIL-A21-1 animal research program was designed to assess the seizure-inhibiting activity and efficacy of DehydraTECH-CBD at lower doses than were required with Epidiolex. Through the program, Lexaria hoped to demonstrate superior performance based on the increased systemic delivery and brain uptake induced by the DehydraTECH platform (https://ibn.fm/UFidI).
The EPIL-A21-1 study program used an established, vehicle-controlled, acute animal seizure model induced by electrical stimulation (“MES”) and was designed as a three-part series, each using Sprague Dawley rats. In the pilot study, which involved 21 animals and examined three different doses, it was established that at lower doses of 50 mg/kg and 75 mg/kg, DehydraTECH-CBD was more efficacious than Epidiolex in reducing or eliminating seizure activity.
More specifically, at the lower 50 mg/kg dose, only DehydraTECH-CBD showed some effectiveness in reducing seizure activity. In contrast, at 75 mg/kg, DehydraTECH-CBD demonstrated complete elimination of seizure activity in 66.6% of the animals compared to 50% of animals treated with Epidiolex. However, Epidiolex was more efficacious than DehydraTECH-CBD in eliminating seizure activity at 100 mm/kg, the highest dose tested in the first study. Overall, these findings suggest that DehydraTECH-CBD is more efficacious at lower doses than Epidiolex.
The second MES animal seizure study was a time-to-peak efficacy study that involved 24 animals. At minute 30, 50% of the animals dosed with DehydraTECH-CBD showed partial reduction or full elimination of seizure activity, while 100% of the rates that received Epidiolex still exhibited full seizure activity at this time point. At 60 minutes post-dosing, 87.5% of rats dosed with DehydraTECH-CBD showed partial reduction or full elimination of seizure activity, whereas only 62.5% of those that received Epidiolex exhibited a similar outcome. At later time points, however, Epidiolex resulted in some enhanced seizure reduction capabilities.
Lexaria is currently undertaking additional work under the EPIL-A21-1 program. Designed to establish the dose needed to achieve seizure inhibition in 50% of the animals tested or ED50, a common performance metric in preclinical animal studies, this final study is meant to corroborate the findings reported to date. This third study is expected to involve 24 animals, with Lexaria expecting to provide further updates as and when they become available.
The findings so far suggest that DehydraTECH-CBD is more effective at lower doses and faster acting than Epidiolex. Still, Lexaria is considering optimizing the DehydraTECH-CBD formulation to facilitate more sustained action in reducing or eliminating seizure activity and is contemplating additional work to reinforce its growing success in seizure prevention.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About TinyGems
TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.
To receive SMS text alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.com
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com
TinyGems is part of the InvestorBrandNetwork
